Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Cencora (COR) reported robust Q3 2025 results, with revenue reaching $80.66 billion, an 8.7% year-over-year increase, exceeding the Zacks Consensus Estimate by 0.41%. Earnings per share (EPS) came in at $4.00, representing a 5.82% positive surprise over the $3.78 consensus. Both U.S. and International Healthcare Solutions segments surpassed their respective revenue estimates. Despite these strong financial beats, Cencora's shares have underperformed the S&P 500 over the last month, returning -1.9% against the index's +0.5%, though the stock maintains a Zacks Rank #2 (Buy) suggesting potential near-term outperformance.

Analysis

Cencora (COR) reported a robust financial performance for its third quarter of fiscal 2025, exceeding analyst expectations on both revenue and earnings. The company posted total revenue of $80.66 billion, an 8.7% year-over-year increase that surpassed the consensus estimate of $80.33 billion. Earnings per share were particularly strong at $4.00, representing a 5.82% positive surprise against the $3.78 estimate and a significant uplift from the $3.34 reported in the year-ago quarter. Growth was supported by both primary segments, with the International Healthcare Solutions division showing notable strength by growing 10.5% YoY to $7.79 billion, well ahead of the $7.3 billion analyst forecast. The larger U.S. Healthcare Solutions segment also grew a solid 8.5% YoY. Despite these strong fundamental results, Cencora's stock has shown recent weakness, underperforming the broader market with a -1.9% return over the past month compared to the S&P 500's +0.5% gain. This disconnect between operational performance and share price may be a key focus, especially given the stock's current Zacks Rank #2 (Buy) designation, which implies potential for near-term outperformance.

Key Decisions for Investors

• Investors should view the significant 5.82% EPS beat and 10.5% YoY growth in the International Healthcare Solutions segment as a strong confirmation of the company's operational health.
• The recent share price decline of -1.9% against a backdrop of strong fundamental results and positive earnings surprises may represent a dislocation, offering a potential entry point for investors who believe the market will eventually reward the performance.
• It is now critical to monitor if this robust earnings report can serve as the catalyst needed to reverse the stock's recent negative momentum and close its performance gap with the broader market.